Nanexa ABFRA:40M -2.89%53 Gross Margin % is 374.34% as of Mar. 2026, which is 49% below its 10-year median of 740.75. GuruFocus rates FRA:40M with a GF Score™ of 53/100 and a GF Value™ of €0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 935 Drug Manufacturers companies, Nanexa AB ranks better than 99.79% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Nanexa AB's Gross Profit for the
three
months ended in Mar. 2026 was €0.57 Mil. Nanexa AB's Revenue for the
three
months ended in Mar. 2026 was €0.15 Mil. Therefore, Nanexa AB's Gross Margin % for the quarter that ended in Mar. 2026 was 374.34%.
Warning Sign:
Nanexa AB gross margin has been in long-term decline. The average rate of decline per year is -33.7%.
The historical rank and industry rank for Nanexa AB's Gross Margin % or its related term are showing as below:
FRA:40M'
s Gross Margin % Range Over the Past 10 Years
Min: 154.74 Med: 740.75 Max: 3100
Current: 155.88
During the past 12 years, the highestGross Margin % of Nanexa AB was 3100.00%. The lowest was 154.74%. And the median was 740.75%.
FRA:40M's Gross Margin % is ranked better than 99.79% of 935
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs FRA:40M: 155.88
Nanexa AB had a gross margin of 374.34% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nanexa AB was -33.70% per year.
Nanexa AB (FRA:40M) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nanexa AB had a gross margin of 374.34% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nanexa AB Gross Margin % Related Terms
Nanexa AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nanexa AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nanexa AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanexa AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nanexa AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nanexa AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nanexa AB (FRA:40M) has a Gross Margin % of 374.34% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanexa AB and its competitors. This is 49% below median its historical median of 740.75. Over the past decade, Nanexa AB's Gross Margin % has ranged from 154.74 to 3,100.00. According to the industry distribution chart, Nanexa AB ranks #2 out of 935 companies in the Drug Manufacturers industry, placing it in the top 0.2%.
Is Nanexa AB's Gross Margin % too high?
Nanexa AB's current Gross Margin % of 374.34% is 49% below median its 10-year median of 740.75. Over the past 10 years, this metric has ranged from a low of 154.74 to a high of 3,100.00. The Drug Manufacturers industry median Gross Margin % is 48.54. Nanexa AB's value of 374.34% is 671.2% above this industry median. Based on the distribution chart, Nanexa AB ranks #2 out of 935 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nanexa AB has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nanexa AB's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nanexa AB ranks #2 out of 935 companies for Gross Margin %. This places Nanexa AB in the top 0% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Nanexa AB's value of 374.34% is 671.2% above this benchmark. Historically, Nanexa AB's own Gross Margin % has ranged from 154.74 to 3,100.00 over the past decade. While the company's 10-year median is 740.75 vs. the industry median of 48.54, Nanexa AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nanexa AB's current Gross Margin % of 374.34% is 671.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nanexa AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nanexa AB's current Gross Margin % is 374.34%, which is 49% below median its own 10-year median of 740.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanexa AB stock overvalued right now?
Based on GuruFocus' analysis, Nanexa AB (FRA:40M) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.17, compared to a current price of €0.30 — trading 77.9% above its estimated fair value. The current Gross Margin % is 374.34%, which is 49% below median its 10-year median of 740.75 and 671.2% above the Drug Manufacturers industry median of 48.54. Nanexa AB's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nanexa AB (FRA:40M), the current Gross Margin % is 374.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanexa AB (FRA:40M) Overvalued in 2026?
Based on GuruFocus' analysis, Nanexa AB stock appears to be overvalued.
The current stock price of €0.30 is trading 77.9% above its estimated GF Value™ of €0.17.
GuruFocus considers Nanexa AB to be Significantly Overvalued.
Key valuation signals for FRA:40M:
Gross Margin %: 374.34% (49% below median its 10-year median of 740.75)
GF Value™: €0.17 vs. price of €0.30 (77.9% above fair value)
Industry Position: 671.2% above the Drug Manufacturers median (#2 of 935)
No single metric tells the full story. See the FRA:40M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanexa AB is a pharmaceutical company developing injectable drug products based on the proprietary drug delivery system PharmaShell - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. The company develops its products and also has collaboration agreements with several pharma companies, among others AstraZeneca. Geographically, the company derives maximum revenue from Nordic countries, while it also has its presence in Europe (excluding the Nordic countries), North America, and Asia.
53GF Score
Get the complete analysis for FRA:40M
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:40M has been successfully added to your 
